Fellowship Opportunity

Attention Doctor of Pharmacy Candidates and Recent Graduates!

St. John’s University College of Pharmacy and Health Sciences is proud to announce new fellowship opportunities in collaboration with two industry partners: PTC Therapeutics and Myovant Sciences. We will be launching our recruitment efforts for our new fellowships, which begin on or about July 1, 2023, in the following areas next week:

PTC Therapeutics:

• One position in Global Regulatory Affairs

Myovant Sciences:

• One position in Clinical Regulatory Affairs

• One position in Commercial Regulatory Affairs

• One position in Early Clinical Development

The college and our affiliated partners will be hosting webinars on the following dates:

• Tuesday October 25th, 2022 – 8:00pm EDT

St. John’s University/PTC Therapeutics – register HERE

• Wednesday October 26th, 2022 – 8:00pm EDT

St. John’s University/Myovant Sciences – register HERE

To learn more about all our programs, visit our fellowship website at the address below:

https://www.stjohns.edu/resources/places/pharmaceutical-industry-fellowship-programs

Applications are being accepted NOW!

To apply, the following materials must be emailed to the fellowship program leadership at St. John’s University using the email address stjfellowships@stjohns.edu . Programmatic interviews will be conducted virtually during the month of November.

Early Application material deadlines for the above programs are listed below:

Required Item Deadline

Curriculum Vitae November 4, 2022

Letter of Intent November 4, 2022

Official College Transcript November 8, 2022

Three Letters of Recommendation November 8, 2022

Thank you, and we look forward to receiving your applications!

If you have any questions, please contact us at stjfellowships@stjohns.edu .

Best,

Bill Maidhof

This email may contain proprietary, confidential and/or privileged material for the sole use of the intended recipient(s). Any review, use, distribution or disclosure by others is strictly prohibited. If you are not the intended recipient (or authorized to receive for the recipient), please contact the sender by reply email and delete all copies of this message.